Login to Your Account

Earnings Roundup

Provenge Sales Disappoint, but Dendreon Shows Growth

By Catherine Shaffer
Staff Writer

Monday, November 5, 2012
Dendreon Corp. reported its third-quarter earnings, handing in a net loss of $154.9 million, or $1.04 per share. That loss was larger than consensus estimates. Provenge (sipuleucel-T) revenues also fell short of consensus, at $78 million, vs. $80.7 million.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription